Should I Buy PDEX? PDEX 2026 Analysis

Should You Buy Pro-Dex Inc (PDEX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

39.230

1 Day change

-0.44%

52 Week Range

70.260

Analysis Updated At

2026/01/30

Not a good buy right now for an impatient investor. Despite solid Q2 growth, the near-term technical setup is bearish (downtrend with weakening momentum) and Intellectia signals show no buy edge today. I would hold off on buying at the current pre-market price (~39.41) and only consider entry if price reclaims the pivot (~40.88) and holds above it.

Technical Analysis

Pre-market price is ~39.405, sitting just above first support S1 (39.028) and below the pivot (40.877), which keeps the stock in a weak technical posture. - Trend: Bearish, with SMA_200 > SMA_20 > SMA_5 (clear downtrend across timeframes). - Momentum: MACD histogram at -0.304 and negatively expanding suggests downside momentum is increasing rather than stabilizing. - RSI(6): 39.16 is near the lower end of neutral (tilting toward oversold, but not showing a strong reversal signal). - Levels: Support at 39.03 then 37.89; resistance/pivot at 40.88, then 42.73. - Pattern-based forecast: Similar-pattern stats imply mild upside next day (+1.88% probability outcome), but negative bias over 1 week (-0.65%) and especially 1 month (-4.61%), aligning with the bearish trend. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

- Earnings/financial momentum: 2026/Q2 showed continued growth (revenue +11.14% YoY, EPS +8.20% YoY) and improved gross margin (+1.89% YoY), which can support valuation over time.
- News tone is generally supportive: the latest update highlights stable performance in the surgical tools market and a profitable quarter (GAAP EPS $0.66).

Neutral/Negative Catalysts

- Technical downtrend: bearish moving averages and a falling MACD histogram indicate the path of least resistance remains down.
- Event catalyst risk appears limited in the near term: only one earnings-related news item provided; no additional upcoming catalysts noted.
- Sentiment/flow: Hedge funds and insiders are both described as neutral with no significant recent trend, suggesting no strong sponsorship or urgency to re-rate the stock upward right now.

Financial Performance

Latest quarter: 2026/Q2. - Revenue: 18.663M, +11.14% YoY (healthy top-line growth). - Net income: 2.187M, +7.21% YoY (profit growth, slightly slower than revenue). - EPS: 0.66, +8.20% YoY (steady earnings expansion). - Gross margin: 30.77%, +1.89% YoY (margin improvement supports quality of earnings). Overall: fundamentals are improving, but the market/price action is not confirming it yet in the short term.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price-target change data was provided, so no clear Wall Street consensus trend can be assessed. Wall Street-style pros vs cons based on provided data: - Pros: consistent YoY growth in revenue/EPS and improving gross margin; profitable quarter. - Cons: current price action/indicators are bearish; limited evidence of strong institutional/insider accumulation; near-term pattern stats skew negative over the next month. Politicians / influential figures: No recent congress trading data available in the last 90 days (and no other political/influential trading information provided).

Analyst Rating

Wall Street analysts forecast PDEX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PDEX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 39.405

Low

Averages

High